These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 27594341

  • 21. Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs.
    Harkin CP, Pagel PS, Tessmer JP, Warltier DC.
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):179-88. PubMed ID: 7475041
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan.
    Papp Z, Csapó K, Pollesello P, Haikala H, Edes I.
    Cardiovasc Drug Rev; 2005 Aug; 23(1):71-98. PubMed ID: 15867949
    [Abstract] [Full Text] [Related]

  • 23. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships.
    Givertz MM, Andreou C, Conrad CH, Colucci WS.
    Circulation; 2007 Mar 13; 115(10):1218-24. PubMed ID: 17339544
    [Abstract] [Full Text] [Related]

  • 24. Effects of calcium sensitizers on intracellular calcium handling and myocardial energetics.
    Hasenfuss G, Pieske B, Kretschmann B, Holubarsch C, Alpert NR, Just H.
    J Cardiovasc Pharmacol; 1995 Mar 13; 26 Suppl 1():S45-51. PubMed ID: 8907130
    [Abstract] [Full Text] [Related]

  • 25. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
    Zimmermann N, Boknik P, Gams E, Herzig JW, Neumann J, Scholz H.
    Eur J Cardiothorac Surg; 1998 Jul 13; 14(1):70-5. PubMed ID: 9726618
    [Abstract] [Full Text] [Related]

  • 26. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L.
    Curr Cardiol Rep; 2000 May 13; 2(3):233-43. PubMed ID: 10980898
    [Abstract] [Full Text] [Related]

  • 27. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA.
    J Card Fail; 2005 Aug 13; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract] [Full Text] [Related]

  • 28. Reversible Covalent Binding to Cardiac Troponin C by the Ca2+-Sensitizer Levosimendan.
    Robertson IM, Pineda-Sanabria SE, Yan Z, Kampourakis T, Sun YB, Sykes BD, Irving M.
    Biochemistry; 2016 Nov 01; 55(43):6032-6045. PubMed ID: 27673371
    [Abstract] [Full Text] [Related]

  • 29. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan.
    Haikala H, Kaheinen P, Levijoki J, Lindén IB.
    Cardiovasc Res; 1997 Jun 01; 34(3):536-46. PubMed ID: 9231037
    [Abstract] [Full Text] [Related]

  • 30. Levosimendan: a unique approach to the treatment of heart failure.
    Nawarskas JJ, Anderson JR.
    Heart Dis; 2002 Jun 01; 4(4):265-71. PubMed ID: 12147186
    [Abstract] [Full Text] [Related]

  • 31. Levosimendan: from basic science to clinical practice.
    Parissis JT, Rafouli-Stergiou P, Paraskevaidis I, Mebazaa A.
    Heart Fail Rev; 2009 Dec 01; 14(4):265-75. PubMed ID: 19101796
    [Abstract] [Full Text] [Related]

  • 32. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass.
    Stocker CF, Shekerdemian LS, Nørgaard MA, Brizard CP, Mynard JP, Horton SB, Penny DJ.
    Crit Care Med; 2007 Jan 01; 35(1):252-9. PubMed ID: 17133188
    [Abstract] [Full Text] [Related]

  • 33. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA, Wagstaff AJ.
    Drugs; 2003 Jan 01; 63(23):2651-71. PubMed ID: 14636085
    [Abstract] [Full Text] [Related]

  • 34. Cardiac Ca2+ signaling and Ca2+ sensitizers.
    Endoh M.
    Circ J; 2008 Dec 01; 72(12):1915-25. PubMed ID: 18981594
    [Abstract] [Full Text] [Related]

  • 35. The clinical experience with levosimendan in anesthesiology and in the intensive care unit.
    Cavana M, Pignataro C, Fraticelli A, Mebazaa A.
    Ital Heart J; 2003 May 01; 4 Suppl 2():61S-64S. PubMed ID: 14635372
    [Abstract] [Full Text] [Related]

  • 36. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A, Planken U, Sandell EP.
    Eur J Clin Pharmacol; 1996 May 01; 49(6):451-8. PubMed ID: 8706769
    [Abstract] [Full Text] [Related]

  • 37. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B, Prasad AS, Economides C, Singh BN.
    J Cardiovasc Pharmacol Ther; 2008 Dec 01; 13(4):269-78. PubMed ID: 19087950
    [Abstract] [Full Text] [Related]

  • 38. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM, Akhter MW.
    Minerva Cardioangiol; 2005 Dec 01; 53(6):565-84. PubMed ID: 16333239
    [Abstract] [Full Text] [Related]

  • 39. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
    Biala A, Martonen E, Kaheinen P, Levijoki J, Finckenberg P, Merasto S, Louhelainen M, Muller DN, Luft FC, Mervaala E.
    Hypertens Res; 2010 Oct 01; 33(10):1004-11. PubMed ID: 20811386
    [Abstract] [Full Text] [Related]

  • 40. Effects of levosimendan on myocardial contractility and oxygen consumption.
    Todaka K, Wang J, Yi GH, Stennett R, Knecht M, Packer M, Burkhoff D.
    J Pharmacol Exp Ther; 1996 Oct 01; 279(1):120-7. PubMed ID: 8858984
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.